On May 26, CARsgen Therapeutics-B declined 5.2% in regular trading, trading at HK$17.6/share, with trading volume of HK$48.90 million.

The decline was primarily driven by the dilutive impact of a recent discounted share placement. On May 15, the company entered into an agreement with major shareholder Yijie Biotechnology and joint placing agents to place 23.7 million shares to no fewer than six independent professional investors on a top-up basis, representing approximately 3.99% of the enlarged share capital. The placement price was set at HK$19.84 per share, a discount of approximately 9.49% to the May 14 closing price of HK$21.92, with estimated net proceeds of approximately HK$462 million.

Additionally, on May 19, a shareholder transferred shares from UBS Securities Hong Kong to Citibank, involving a position worth HK$432 million representing a 4% stake, further weighing on market sentiment. The broader Hong Kong-listed innovative drug sector has also been under pressure recently amid a global bond selloff, with higher interest rate expectations compressing industry valuations and intensifying selling in individual names.

CARsgen Therapeutics is a biopharmaceutical company focused on developing CAR-T cell therapies for hematological malignancies, solid tumors, and autoimmune diseases, with key products including Zevorcabtagene Autoleucel and CT053.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)